Tavneos (avacopan) Coverage Policy
Customize your policy alerts
Sign up for blue cross blue shield - south dakota Policy 05.04.52 alerts
Get alerted when Policy 05.04.52 changes without checking for updates manually.
Monitor payer policy activity
This policy governs coverage and prior authorization for Tavneos (avacopan) as adjunctive treatment for adults with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis or microscopic polyangiitis. Coverage requires documented clinical criteria, specialist prescribing or consultation for initial requests, and applicable benefit eligibility.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.